Stock Scorecard
Stock Summary for Trinity Biotech Plc (TRIB) - $0.72 as of 2/2/2026 9:26:06 AM EST
Total Score
5 out of 30
Safety Score
10 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TRIB
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TRIB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TRIB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TRIB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TRIB (10 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for TRIB
Financial Details for TRIB
Company Overview |
|
|---|---|
| Ticker | TRIB |
| Company Name | Trinity Biotech Plc |
| Country | USA |
| Description | Trinity Biotech plc is a leading innovator in the medical diagnostics sector, specializing in the development and commercialization of advanced diagnostic solutions for clinical laboratories and point-of-care applications. Based in Bray, Ireland, the company has established a significant global presence, catering to the growing demand for rapid and reliable diagnostic tools across multiple regions including the United States, Europe, Africa, and Asia. With a strong commitment to enhancing patient outcomes, Trinity Biotech is continuously expanding its diverse product portfolio through innovative technologies, positioning itself as a pivotal player in the evolving healthcare diagnostics landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 0.72 |
| Price 4 Years Ago | 4.95 |
| Last Day Price Updated | 2/2/2026 9:26:06 AM EST |
| Last Day Volume | 191,926 |
| Average Daily Volume | 6,467,666 |
| 52-Week High | 1.97 |
| 52-Week Low | 0.48 |
| Last Price to 52 Week Low | 50.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 54.83 |
| Sector PE | 188.49 |
| 5-Year Average PE | 2.83 |
| Free Cash Flow Ratio | 10.29 |
| Industry Free Cash Flow Ratio | 19.78 |
| Sector Free Cash Flow Ratio | 30.14 |
| Current Ratio Most Recent Quarter | 1.03 |
| Total Cash Per Share | 0.07 |
| Book Value Per Share Most Recent Quarter | -1.96 |
| Price to Book Ratio | 5.11 |
| Industry Price to Book Ratio | 3.56 |
| Sector Price to Book Ratio | 57.14 |
| Price to Sales Ratio Twelve Trailing Months | 0.33 |
| Industry Price to Sales Ratio Twelve Trailing Months | 6.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.56 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 18,632,000 |
| Market Capitalization | 13,415,040 |
| Institutional Ownership | 65.77% |
Dividends |
|
| Ex-Dividend Date | 6/5/2015 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 1.1000 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 4.88% |
| 5-Year Dividend Growth Rate Percentage | 21.79% |
| All-Time Dividend Growth Rate Percentage | 21.79% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -77.30% |
| Annual Earnings Growth | -32.35% |
| Reported EPS 12 Trailing Months | -1.80 |
| Reported EPS Past Year | -1.64 |
| Reported EPS Prior Year | -6.28 |
| Net Income Twelve Trailing Months | -35,630,734 |
| Net Income Past Year | -31,789,000 |
| Net Income Prior Year | -24,018,000 |
| Quarterly Revenue Growth YOY | 18.10% |
| 5-Year Revenue Growth | -7.41% |
| Operating Margin Twelve Trailing Months | -42.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,341,000 |
| Total Cash Past Year | 5,167,000 |
| Total Cash Prior Year | 3,691,000 |
| Net Cash Position Most Recent Quarter | -86,451,000 |
| Net Cash Position Past Year | -82,625,000 |
| Long Term Debt Past Year | 87,792,000 |
| Long Term Debt Prior Year | 54,651,000 |
| Total Debt Most Recent Quarter | 87,792,000 |
| Equity to Debt Ratio Past Year | -0.67 |
| Equity to Debt Ratio Most Recent Quarter | -1.65 |
| Total Stockholder Equity Past Year | -35,181,000 |
| Total Stockholder Equity Prior Year | -23,949,000 |
| Total Stockholder Equity Most Recent Quarter | -54,715,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -8,803,358 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.47 |
| Free Cash Flow Past Year | -14,255,000 |
| Free Cash Flow Prior Year | -12,360,000 |
Options |
|
| Put/Call Ratio | 3.33 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.02 |
| MACD Signal | -0.05 |
| 20-Day Bollinger Lower Band | 0.69 |
| 20-Day Bollinger Middle Band | 0.95 |
| 20-Day Bollinger Upper Band | 1.21 |
| Beta | 0.50 |
| RSI | 53.03 |
| 50-Day SMA | 0.87 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 3.05 |
System |
|
| Modified | 1/31/2026 9:23:36 AM EST |